Fwd: Mark C Petrie - new articles

[Okechukwu Ogah]

Dr O.S Ogah. MBBS, MSc, PhD, MD, FWACP, FACP, FESC, FNCS

A. Senior Lecturer

Cardiology Unit, Department of Medicine,

Faculty of Clinical Sciences

College of Medicine,

University of Ibadan, NIGERIA

B. Honorary Consultant Physician/Cardiologist,

Cardiology Unit,

Department of Medicine

University College Hospital Ibadan, NIGERIA

PERSONAL POSTAL ADDRESS

P.O BOX 14343, UNIVERSITY OF IBADAN  POST OFFICE

IBADAN, NIGERIA

Tel. +234 806 77 47 121
Fax. +1215-975-6817 (Electronic)
Emails: 

oso...@com.ui.edu.ng ,

osoga...@gmail.com

osoga...@yahoo.com

https://www.researchgate.net/profile/Okechukwu_Ogah4/contributions

C. Bernard Lown Visiting Scholar in Cardiovascular Health

Department of Global Health and Population

Harvard T.H. Chan School of Public Health

Email: oo...@hsph.harvard.edu

D. Adjunct Researcher,

Institute of Advanced Medical Research and Training (IAMRAT)

College of Medicine, University of Ibadan, NIGERIA

E. Affiliate Member,

The Hatter Institute for Cardiovascular Research in Africa (HICRA)

4th Floor Chris Barnard Building
Faculty of Health Sciences
University of Cape Town
Private Bag X3 7935
Observatory, SOUTH AFRICA

http://www.hatter.uct.ac.za/icra/about/staff/visiting-researchers

F. Past President,

Nigerian Cardiac Society

--------------------------------------------------------------------------------------------------------------------------------------------------

"For with thee is the fountain of life: in thy light shall we see light." Psalm 36:9

-------------------------------------------------------------------------------------------------

---------- Forwarded message ---------
From: Google Scholar Alerts <scholarale...@google.com>
Date: Thu, May 9, 2024 at 12:28 AM
Subject: Mark C Petrie - new articles
To: <osoga...@gmail.com>

Use of medical therapy and risk of clinical events according to frailty in heart failure patients-A real-life cohort study.

JE Strange, E Fosbøl, CH Garred, M Elmegaard… - European Journal of Heart …, 2024

Aims Although recent randomized clinical trials have demonstrated the advantages
of heart failure (HF) therapy in both frail and not frail patients, there is insufficient
information on the use of HF therapy based on frailty status in a real-world setting …

 

This message was sent by Google Scholar because you're following new articles written by Mark C Petrie.

List alerts

Cancel alert

[Okechukwu Ogah]

[PDF] Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial

SD Solomon, JW Ostrominski, M Vaduganathan… - European Journal of Heart …, 2024

Aims To describe the baseline characteristics of participants in the FINEARTS‐HF
trial, contextualized with prior trials including patients with heart failure (HF) with
mildly reduced and preserved ejection fraction (HFmrEF/HFpEF). The FINEARTS‐HF …

[Okechukwu Ogah]

[HTML] Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials

SJ Shah, K Sharma, BA Borlaug, J Butler, M Davies… - European Heart Journal, 2024

Abstract Background and Aims In the STEP-HFpEF trial program, treatment with
semaglutide resulted in multiple beneficial effects in patients with obesity-related
heart failure with preserved ejection fraction (HFpEF). Efficacy may vary according to …

[PDF] Sodium zirconium cyclosilicate in patients with HFrEF and hyperkalemia: REALIZE-K rationale, design, and baseline characteristics

MN Kosiborod, D Cherney, K Connelly, AS Desai… - JACC: Heart Failure, 2024

Abstract Background Mineralocorticoid receptor antagonists (MRAs) improve
outcomes in patients with heart failure and reduced ejection fraction (HFrEF).
However, MRAs are often underused due to hyperkalemia concerns. Objectives To …

[HTML] Semaglutide and NTproBNP in Obesity-Related HFpEF: Insights from STEP-HFpEF Program

MC Petrie, BA Borlaug, J Butler, MJ Davies… - Journal of the American …, 2024

Background The glucagon-like peptide-1 receptor agonist, semaglutide, improved
health status and reduced body weight in patients with obesity-related heart failure
(HF) with preserved ejection fraction (HFpEF) in the STEP-HFpEF Program. Whether …